• / Free eNewsletters & Magazine
  • / My Account
Home>Mylan Rejects Teva's Unsolicited $40 Billion Bid--4th Update

Mylan Rejects Teva's Unsolicited $40 Billion Bid--4th Update

3party Content

Tue, 28 Apr 2015

By Ed Silverman Mylan NV Executive Chairman Robert Coury on Monday issued a stinging rebuke of Teva Pharmaceutical Industries Ltd.'s unsolicited bid, using terms harsh even for the sharp-elbowed world of deal making to explain why the generic-drug maker's board rejected the $40 billion deal. In a
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.